CVRx, Inc. CVRX 深 滬
等待開盤 07-18 09:30:00 美东时间
8.35
-0.100
-1.18%
華盛通- 最 高8.85
- 今 開8.56
- 成交量 53.90万股
- 最 低 8.21
- 昨 收 8.45
- 總市值 2.18亿
- 52周最高 18.55
- 市盈率 靜 --
- 換手率 2.07%
- 52周最低 4.2993
- 委 比 52.94%
- 總股本 2607.26万
- 歷史最高 33.135
- 量 比 1.70
- 振 幅 7.57%
- 歷史最低 4.2993
- 每 手 1
- 風險率 3.46%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多CVRx's Barostim Implant Set for $45K Medicare Reimbursement Under Proposed Outpatient Rule
CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, announced today that the Centers for Medicare and Medicaid Services (CMS) has proposed to keep the Barostim implant procedure as part of the
07-16 19:32
CVRx Announces Positive News on Outpatient Payment for Barostim
CVRx announced that CMS has proposed maintaining the Barostim implant procedure in APC 1580 with an approximate $45,000 payment for outpatient procedures. CMS is also seeking comments on a potential Level 6 Neurostimulator APC. This follows positive developments in reimbursement rates, including a higher MS-DRG for inpatient procedures and transitioning to Category I CPT codes for physician payments. These updates highlight the clinical value of ...
07-16 11:30
CVRx to Present at the William Blair 45th Annual Growth Stock Conference
CVRx, Inc. announced that its management team will present at the William Blair 45th Annual Growth Stock Conference on June 4, 2025. The presentation will be held via webcast at 10:00am Central Time and will be available on the company's investor relations page. CVRx specializes in developing neuromodulation solutions for cardiovascular diseases, with its Barostim device approved by the FDA for heart failure treatment. The company is listed on NA...
05-28 20:30
美股大行评级 | 潜在涨幅754.7%！HC Wainwright & Co.：Alector获机构升目标价至10美元，维持"买入"评级
潜在涨幅754.7%！HC Wainwright & Co.：Alector获机构升目标价至10美元，维持"买入"评级
05-10 10:00
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Regencell Bioscience (NASDAQ:RGC) stock moved upwards by 43.9% to $305...
05-10 01:06
JP Morgan Downgrades CVRx to Underweight, Lowers Price Target to $7
JP Morgan analyst Robbie Marcus downgrades CVRx (NASDAQ:CVRX) from Neutral to Underweight and lowers the price target from $15 to $7.
05-09 19:37
CVRx Q1 EPS $(0.53) Beats $(0.56) Estimate, Sales $12.30M Miss $13.38M Estimate
CVRx (NASDAQ:CVRX) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(0.56) by 5.36 percent. This is a 49.04 percent increase over losses of $(1.04) per share from the same
05-09 04:24
Earnings Scheduled For May 8, 2025
Companies Reporting Before The Bell • Sempra (NYSE:SRE) is likely to report qua...
05-08 16:33
美股大行评级 | 超多美股遭下调评级！高盛：下调美国航空集团评级至"卖出"，目标价从16美元下调至8美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1117013356914663424.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持FTC Solar(FTCI)"买入"评级，目标价从1.5美元升至5美元</p> <p>• 摩根士丹利：维持艾伯维(ABBV)"超配"评级，目标价从239美元升至241美
04-10 09:00
美股大行评级 | 潜在涨幅147.43%！HC Wainwright & Co.上调Pacira BioSciences目标价至65美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1116650478822592513.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Pacira BioSciences(PCRX)"买入"评级，目标价从48美元升至65美元</p> <p>• 瑞穗：上调Amylyx Pharmaceuticals(AM
04-09 08:50
